Working groups
Jessica is consultant gastroenterologist at St Vincent's Hospital and The Royal Melbourne Hospital, with a research interest in liver cancer and viral hepatitis.
She completed my PhD exploring the role of the innate immune system in hepatitis C disease post liver transplantation. She received an NHMRC Sidney Sax Early Career Research Fellowship for post-doctoral studies at Imperial College London (Department of Hepatology), where she worked with a team on public health projects targeting reduction of HBV-related liver disease and liver cancer in Sub-saharan Africa and exploring genetic mutation analysis of circulating free tumour DNA in liver cancer in collaboration with Cologne University (Germany).
Jessica is currently working on further projects exploring genetics of liver cancer and the epidemiology of liver disease and liver cancer under the mentorship of Professor Margaret Hellard. She is involved in hepatology training and public health projects in Fiji.
Drug and Alcohol Review
Michael Livingston, Nicholas Taylor, Jessica Howell, M. David Curtis, Paul Dietze
PLoS ONE
Dina Moussa, Joseph Doyle, Jack Wallace, Jessica Howell, Dina Moussa, Joseph Doyle, Jack Wallace, Jessica Howell
PLoS ONE
Dina Moussa, Joseph Doyle, Jack Wallace, Jessica Howell, Dina Moussa, Joseph Doyle, Jack Wallace, Jessica Howell
We describe the prevalence and clinical impact of concurrent liver diseases among people undergoing liver transplantation for liver cirrhosis and liver cancer in Australia and New Zealand
This project delivers hepatitis C prevention, testing and treatment services and hepatitis B testing and vaccination services.
People with hepatocellular carcinoma risk factors are recommended to have twice-yearly cancer screenings. We explore barriers to screening adherence.
This project assessed the approach of providing hepatitis B tests to potential new migrants from endemic countries.
This pilot and feasibility study aimed to increase hepatitis B testing in Melbourne’s Chinese community.
This project addresses critical knowledge gaps in Australian and global efforts to eliminate hepatitis C as a public health threat by 2030.
Burnet projects aimed at reducing the burden of hepatitis B in Australia and STIs will be supported by NHMRC Investigator Grants.
Newly published Burnet study demonstrates the feasibility and effectiveness of simplified treatment of hepatitis C in Myanmar.